--- title: "ARS Pharmaceuticals (SPRY) news: class action" url: "https://aibio.space/companies/ars-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SPRY class action news: ARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline. ARS Pharmaceuticals, Inc." --- SPRY ARS Pharmaceuticals, Inc. NASDAQ · United States # ARS Pharmaceuticals (SPRY) news SPRY class action news Legal · 2026-08-13 ## [ARS Pharmaceuticals details Aptar trade secret suit and its own antitrust claim over neffy parts](https://aibio.space/news/ars-pharmaceuticals-details-aptar-trade-secret-suit-own-antitrust/) AptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026. ## Latest ARS Pharmaceuticals news 1. 2026-08-13 Legal [ARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline](https://aibio.space/news/ars-pharmaceuticals-faces-securities-class-action-neffy-insurance/) A stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July. ## ARS Pharmaceuticals at a glance - **Ticker**: SPRY - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $143.8 million ### Related companies - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) NASDAQ: TPST - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) AMEX: PLX - [Outlook Therapeutics](https://aibio.space/companies/outlook-therapeutics/) NASDAQ: OTLK - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) NASDAQ: AYTU - [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) NASDAQ: CNSP ### Also on NASDAQ - [Kamada](https://aibio.space/companies/kamada/) KMDA - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR - [PHIBRO ANIMAL HEALTH CORP](https://aibio.space/companies/phibro-animal-health/) PAHC - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) VKTX - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) XERS - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) AVBP ## What ARS Pharmaceuticals does ARS Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. The company says neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, and that it also has approvals in the U.K., Japan, Australia and China. The text describes it as the first new delivery method for epinephrine in more than 35 years. neffy uses an absorption enhancer called Intravail. The FDA approved neffy 2 mg in August 2024 for adults and children who weigh 30 kg or greater, and approved neffy 1 mg in March 2025 for patients four years of age and older who weigh 15 kg to less than 30 kg. The company estimates there are approximately 40 million people in the U.S. who experience Type I allergic reactions, and that approximately 6.5 million of those with severe reactions were prescribed an epinephrine autoinjector. It runs a direct sales force of 106 individuals to commercialize neffy. | Product or program | What it is | Stage | |---|---|---| | neffy | Needle-free intranasal epinephrine for Type I allergic reactions and anaphylaxis | approved | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/spry-20251231.htm). ## ARS Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$84.3 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | [$89.1 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | | Research and development | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | [$19.6 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | | Net income (loss) | [-$171.3 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | [$8.0 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | | Cash from operations | [-$170.9 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | [$13.5 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | | Cash and equivalents | [$41.3 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349140/) | [$50.8 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | | Short-term investments | [$203.7 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349140/) | [$263.2 million](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.2 million, plus short-term investments of $135.7 million, $143.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ARS Pharmaceuticals Is there a class action against ARS Pharmaceuticals? Our latest story on this, dated Aug 13, 2026: "ARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ars-pharmaceuticals-faces-securities-class-action-neffy-insurance/). What is the ticker symbol of ARS Pharmaceuticals? ARS Pharmaceuticals, Inc. trades under the ticker SPRY on NASDAQ. Where is ARS Pharmaceuticals listed? ARS Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of ARS Pharmaceuticals? The SEC Central Index Key (CIK) for ARS Pharmaceuticals, Inc. is 1671858. Its filings are on SEC EDGAR. How many shares does ARS Pharmaceuticals have outstanding? 99,447,343 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is ARS Pharmaceuticals listed under? Our directory records ARS Pharmaceuticals, Inc. under United States. What does ARS Pharmaceuticals do? Our directory classifies ARS Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of ARS Pharmaceuticals? The ISIN recorded for ARS Pharmaceuticals, Inc. is US82835W1080. Does aibio.space cover ARS Pharmaceuticals? aibio.space lists ARS Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ARS Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does ARS Pharmaceuticals develop? ARS Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. The company says neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, and that it also has approvals in the U.K., Japan, Australia and China. What is neffy from ARS Pharmaceuticals? neffy: Needle-free intranasal epinephrine for Type I allergic reactions and anaphylaxis Stage: approved. What was ARS Pharmaceuticals's revenue last year? $84.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is ARS Pharmaceuticals profitable? ARS Pharmaceuticals, Inc. reported a net loss of $171.3 million for the fiscal year ended Dec 31, 2025, and used $170.9 million of cash in operations, per its annual report to the SEC. How much does ARS Pharmaceuticals spend on research and development? $13.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: ARS Pharmaceuticals Members talk about ARS Pharmaceuticals (SPRY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ARS Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349140/spry-20260630.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SPRY on TradingView](https://www.tradingview.com/symbols/NASDAQ-SPRY/). ## SEC filings and registration - **SEC name**: ARS Pharmaceuticals, Inc. - **CIK**: 1671858 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SPRY (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 - **Phone**: 858-771-9307 - **Shares outstanding**: 99,447,343 as of 2026-08-11 (10-Q filed 2026-08-13) - **Former names**: Silverback Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349140/spry-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312526307773/d168709d8k.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/d157645d8k.htm) filed 2026-07-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312526282994/d26870d8k.htm) filed 2026-06-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1671858/000119312526225142/spry-20260331.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-20260515.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/d10320d8k.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001671858), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ARS Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SPRY, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ARS Pharmaceuticals, Inc. - **Ticker**: SPRY - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US82835W1080 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SPRY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ars-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ARS Pharmaceuticals (SPRY) news: class action", 2026-10-31, https://aibio.space/companies/ars-pharmaceuticals/